Molecular Imaging

SNMMI honors Vasken Dilsizian with two distinctions at 2026 meeting

By AuntMinnie.com staff writers

Vasken Dilsizian, MD, has received the Wagner Lectureship and the Minoshima-Pappas Transformational Leadership Award.

June 1, 2026

SNMMI inducts six new fellows at 2026 annual meeting

By AuntMinnie.com staff writers

The SNMMI named six new fellows during its annual meeting in Los Angeles.

June 1, 2026

SNMMI names Richard Carson recipient of 2026 Aebersold Award

By AuntMinnie.com staff writers

The SNMMI has awarded the Aebersold Award to Richard Carson, PhD, from Yale University.

June 1, 2026

Perceptive Discovery, Certis Oncology team on radiopharmaceuticals

By AuntMinnie.com staff writers

Perceptive Discovery and Certis Oncology are collaborating on preclinical radiopharmaceutical development.

June 1, 2026

SNMMI awards Martin Pomper 2026 Benedict Cassen Prize

By AuntMinnie.com staff writers

The SNMMI has awarded Martin Pomper, MD, PhD, the Benedict Cassen Prize for his contributions toward nuclear medicine research.

June 1, 2026

ASCO: Lu-177 edotreotide yields sustained quality-of-life gains

By Erik L. Ridley

A poster presentation at ASCO 2026 highlighted quantifiable benefits for patients receiving the radiopharmaceutical treatment for GEP-NETs.

May 31, 2026

MTTI highlights two-cycle EBTATE data for neuroendocrine tumors

By AuntMinnie.com staff writers

A clinical study found that EBTATE achieved approximately eight-fold higher tumor uptake compared with conventional (Lu-177)-DOTATATE.

May 31, 2026

GE HealthCare anticipates FDA 510(k) nod for MIM KineticID

By AuntMinnie.com staff writers

Software designed for dynamic PET imaging workflows and quantitative kinetic modeling.

May 29, 2026

Ratio Therapeutics, PharmaLogic expand manufacturing partnership

By AuntMinnie.com staff writers

Agreement supports continued clinical development of actinium 225-based FAP-targeted radiotherapeutic.

May 29, 2026

Shine secures new European clearance

By AuntMinnie.com staff writers

EMA approval follows several recent milestones.

May 29, 2026

Eye movement abnormalities flag brain health risk in ex-racing drivers

By Kate Madden Yee

A case series of 12 male retired professional motorsport drivers showed a high prevalence of mild neurological abnormalities.

May 29, 2026

New tau PET tracer outperforms standard agent in Alzheimer’s disease

By Will Morton

The findings are from a head-to-head comparison between F-18 MK-6240 and F-18 flortaucipir among 682 participants.

May 29, 2026

Page 1 of 628

Next Page